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Abstract 
Background: While intensive Plasmodium falciparum multidrug resistance surveillance continues in Cambodia, 
relatively little is known about Plasmodium vivax drug resistance in Cambodia or elsewhere. To investigate P. vivax anti-
malarial susceptibility in Cambodia, 76 fresh P. vivax isolates collected from Oddar Meanchey (northern Cambodia) in 
2013–2015 were assessed for ex vivo drug susceptibility using the microscopy-based schizont maturation test (SMT) 
and a Plasmodium pan-species lactate dehydrogenase (pLDH) ELISA. P. vivax multidrug resistance gene 1 (pvmdr1) 
mutations, and copy number were analysed in a subset of isolates.
Results: Ex vivo testing was interpretable in 80% of isolates using the pLDH-ELISA, but only 25% with the SMT. Plas-
modium vivax drug susceptibility by pLDH-ELISA was directly compared with 58 P. falciparum isolates collected from 
the same locations in 2013–4, tested by histidine-rich protein-2 ELISA. Median pLDH-ELISA  IC50 of P. vivax isolates was 
significantly lower for dihydroartemisinin (3.4 vs 6.3 nM), artesunate (3.2 vs 5.7 nM), and chloroquine (22.1 vs 103.8 nM) 
than P. falciparum but higher for mefloquine (92 vs 66 nM). There were not significant differences for lumefantrine or 
doxycycline. Both P. vivax and P. falciparum had comparable median piperaquine  IC50 (106.5 vs 123.8 nM), but some P. 
falciparum isolates were able to grow in much higher concentrations above the normal standard range used, attain-
ing up to 100-fold greater  IC50s than P. vivax. A high percentage of P. vivax isolates had pvmdr1 Y976F (78%) and F1076L 
(83%) mutations but none had pvmdr1 amplification.
Conclusion: The findings of high P. vivax  IC50 to mefloquine and piperaquine, but not chloroquine, suggest signifi-
cant drug pressure from drugs used to treat multidrug resistant P. falciparum in Cambodia. Plasmodium vivax isolates 
are frequently exposed to mefloquine and piperaquine due to mixed infections and the long elimination half-life 
of these drugs. Difficulty distinguishing infection due to relapsing hypnozoites versus blood-stage recrudescence 
complicates clinical detection of P. vivax resistance, while well-validated molecular markers of chloroquine resistance 
remain elusive. The pLDH assay may be a useful adjunctive tool for monitoring for emerging drug resistance, though 
more thorough validation is needed. Given high grade clinical chloroquine resistance observed recently in neighbour-
ing countries, low chloroquine  IC50 values seen here should not be interpreted as susceptibility in the absence of 
clinical data. Incorporating pLDH monitoring with therapeutic efficacy studies for individuals with P. vivax will help to 
further validate this field-expedient method.
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Background
Cambodia continues to be at the epicenter of globally 
emerging multidrug resistant malaria. This has prompted 
intensive elimination efforts accompanied by surveillance 
to characterize Plasmodium falciparum resistance. Over 
the past several decades, P. falciparum has developed 
resistance to numerous drugs, particularly in Southeast 
Asia where high grade treatment failures have been doc-
umented [1–4]. Since 2000, the use of artemisinin (ART)-
based combination therapy (ACT) as first-line treatment 
has been implemented in nearly all malaria endemic areas 
to overcome resistance developing as a result of mono-
therapy treatments. However, P. falciparum resistance to 
ART emerged in 2006, just a few years after introduction 
of artesunate–mefloquine (AS–MQ) in Cambodia [5, 
6], and was later confirmed on a large scale by intensive 
multidisciplinary surveillance studies [7]. In 2013, the 
first high grade clinical failures of dihydroartemisinin–
piperaquine (DHA–PPQ) were reported [8]. DHA–PPQ 
had only recently been introduced as first-line therapy in 
Cambodia. Reduced in vitro P. falciparum susceptibility 
to PPQ developed on a background of artemisinin resist-
ance here [9, 10], with specific molecular mechanisms 
elucidated soon thereafter [11, 12].
While intensive surveillance for P. falciparum con-
tinues in Cambodia, little is known about Plasmodium 
vivax drug resistance. Clinical P. vivax resistance is far 
more difficult to characterize due to difficulties distin-
guishing true recrudescence of resistant parasites, rein-
fections with new blood-stage P. vivax infections, and 
relapsing infections by liver stage hypnozoites. Moreo-
ver, inability to maintain long-term culture of P. vivax 
parasites prevents reproducible assessments of parasite 
drug susceptibilities. Plasmodium vivax resistance is 
generally assumed to be less pronounced than P. falcipa-
rum, as blood-stage P. vivax infection remains clinically 
susceptible to most available anti-malarials. CQ resist-
ant P. vivax was first reported in 1989 from Papua New 
Guinea (PNG) and Papua Indonesia [13–16], where CQ 
monotherapy remains ineffective. Chloroquine-resistant 
vivax isolates in this region have been found to harbour 
polymorphisms in the pvmdr1 (P. vivax multidrug resist-
ance 1) gene, whereas amplification of the gene has been 
associated with reduced susceptibility to MQ and other 
drugs in  vitro [17–20]. Sporadic cases of CQ failure 
have since been reported in parts of Southeast Asia and 
South America [21–24], but there is no clear evidence 
that these are associated with pvmdr1 mutations in these 
regions. Thus, the usefulness of this putative drug resist-
ance marker for detecting emerging resistance remains 
uncertain.
Artemisinin-based combination therapy is now recom-
mended for use as first-line agent for all malaria in areas 
of multidrug resistant P. falciparum, particularly where 
clinical failures have been documented [25, 26]. In Cam-
bodia, DHA–PPQ was used as first-line therapy for both 
vivax and falciparum malaria since 2011 to respond to 
declining efficacy of CQ for P. vivax treatment in spe-
cific northern and western provinces where the clinical 
cure rate had dropped to 80–90%, though cure rates have 
remained near 100% elsewhere [27–29]. The approach 
was also implemented to simplify drug administration 
and overcome diagnostic difficulties. Limited diagnostic 
capacity makes distinguishing P. vivax from P. falciparum 
microscopically challenging, despite overall increases in 
diagnostic capacity after years of effort. Frequent relapse 
of latent P. vivax following treatment for blood stage P. 
falciparum infections, and high prevalence of difficult to 
distinguish mixed species infections pose further chal-
lenges. While the use of DHA–PPQ to treat CQ-sensitive 
P. vivax is thought to be effective and convenient [26], it 
may in fact exacerbate resistance to both P. vivax and P. 
falciparum [30].
To investigate P. vivax anti-malarial susceptibility in 
Cambodia, fresh P. vivax isolates collected from North-
ern provinces from 2013 to 2015 were assessed for sen-
sitivity to commonly used drugs in short-term culture. 
Growth inhibition was measured by both the micros-
copy-based schizont maturation test (SMT) and Plasmo-
dium pan-species lactate dehydrogenase (pLDH) ELISA. 
SMT had been considered the conventional method for 
P. vivax drug testing, but not sensitive for low parasitae-
mia samples. It is also labour-intensive and interpretation 
of results is subjective. pLDH ELISA has emerged, offer-
ing notable advantages. pLDH has demonstrated higher 
sensitivity for detection in settings of low P. vivax growth 
rate and very low parasitaemia, improving yields for  IC50 
determination [31]. Results from these assays were then 
compared with those from concurrently collected P. fal-
ciparum isolates analysed in both the novel pLDH assay 
and the previously established HRP-2 assay [32]. Plas-
modium vivax multidrug resistance gene 1 (pvmdr1) 
mutations and copy number, which have been proposed 
as candidate markers for drug resistance, were analyzed 
in a subset of isolates. This is the first report that we are 
aware of that documents ex vivo P. vivax drug suscepti-
bility in Cambodia, and provides baseline data for future 
surveillance and elimination efforts.
Methods
Study site, sample collection and processing
Plasmodium isolates were obtained from volunteers 
with uncomplicated malaria enrolled in an anti-malar-
ial drug resistance surveillance study conducted June 
2013–October 2015, in Oddar Meanchey province, 
northern Cambodia. The study was approved by the 
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Cambodian National Ethics Committee for Health 
Research (NECHR), and the Walter Reed Army Insti-
tute of Research (WRAIR) Institutional Review Board 
(protocol WR1576). All subjects were ≥  13  years old 
without a history of anti-malarial drug use within the 
past 7  days. Diagnosis of malaria was performed using 
Giemsa-stained peripheral blood smears, and confirmed 
later by real-time PCR [9]. A total of 76 P. vivax isolates 
were collected from volunteers with mono P. vivax from 
June 2013 to October 2015, while 58 P. falciparum iso-
lates were collected for comparison from those with 
mono P. falciparum infections from January to August 
2014. After informed consent, patient venous blood sam-
ples were collected in sodium heparin and directly tested 
fresh for ex vivo drug susceptibility within 6 h of phlebot-
omy without blood centrifugation, leukocyte depletion 
or culture adaptation. Additional blood was collected in 
an EDTA tube for molecular marker analysis for P. vivax 
drug resistance.
In the first 29 P. vivax isolates, a portion of heparin-
ized blood was centrifuged, and cell pellets including 
buffy coat were passed through CF11 cellulose (What-
man™, Maidstone, UK) or Plasmodipur filters (EuroPro-
xima, The Netherlands) to remove human white blood 
cells (WBC). WBC depleted samples were tested for 
drug susceptibility side by side with whole blood sam-
ples. Samples were treated with 45% Percoll in only the 
first 3 P. vivax isolates to separate late stage parasites and 
enrich for and synchronize at early stages for the schizont 
maturation test (SMT) [33]. An overall schematic for the 
experiment is shown in Fig. 1.
Preparation of dried drug plates
Dried drug-coated plates were prepared using published 
methods, and tested against the P. falciparum W2 ref-
erence clone for quality control [32, 34]. All drugs were 
provided by Chemical Repository of the Walter Reed 
Army Institute of Research (WRAIR). Briefly, dihydroar-
temisinin (DHA), artesunate (AS), mefloquine hydro-
chloride (MQ), quinine sulfate hydrate (QN), chloroquine 
diphosphate (CQ), and piperaquine phosphate (PPQ) 
were coated onto 96 well plates. Atovaquone (ATQ), 
P. vivax
76 isolates
P. falciparum
58 isolates
Phase I
Jun2013 – Mar2014
Phase II
May2014 – Oct2015
34 isolates 42 isolates
19 isolates 15 isolates
(Ring ≥ 50%) (Ring < 50%)
10 isolates
5 isolates*                                                                                                                   
Heparinize blood Heparinize blood Heparinize blood Heparinize blood
Jan-Aug2014
WBC depleted
2 drug plates 2 drug plates
37°c 24-48 hours
SMT pLDH ELISA
37°c 24-48 hr.
SMT pLDH
WBC depleted
1 plate1 plate
37°c 24-48 hr.
pLDH pLDH
1 plate
37°c 24-48 hr.
pLDH
2 drug plates
37°c 48 hr.
pLDH HRP-2
72 hr.
Fig. 1 Schematic for ex vivo experiments. Plasmodium vivax ex vivo experiments were divided into 2 phases. In Phase I, the schizont maturation test 
(SMT) was performed concurrently with the pLDH ELISA. Blood samples were processed to deplete white blood cells, and incubated with drugs of 
interest in parallel with whole blood samples. The SMT was conducted only in samples with ≥ 50% ring stages. *5 isolates with ring stage < 50% 
in initial samples were not tested for drug susceptibility, but 3 of them had Percoll treatment applied to separate late stage parasites and enrich for 
early stages for the SMT. In phase II, only pLDH ELISA was performed on whole blood samples. For P. falciparum testing, pLDH ELISA was performed 
concurrently with the HRP-2 ELISA with 48 h incubation times used in the pLDH ELISA to ensure meaningful comparison of P. vivax susceptibility, 
while the previously established 72 h incubation was followed for the HRP-2 method
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lumefantrine (LUM), doxycycline (DOX) and artemisone 
(ATM) were added only to later plate lots once the ini-
tial methods had been established, and as a result were 
tested in only 76% (ATQ and LUM), 60% (DOX), and 49% 
(ATM) of isolates, respectively. Final drug concentrations 
(after adding samples) ranged from 0.095 to 70  nM for 
DHA, 0.07 to 52 nM for AS, 0.66 to 482 ng/ml for MQ, 
2.18 to 1596 nM for QN, 5.31 to 3877 nM for CQ, 0.9 to 
674 nM for PPQ, 0.38 to 273 nM for ATQ, 0.13 to 95 nM 
for LUM, 285 to 207,943 nM for DOX, and 0.02 to 25 ng/
ml for ATM. Starting in 2013, some P. falciparum isolates 
were able to grow in extremely high PPQ concentrations 
[35]. From 2014 onward, increased PPQ concentration 
(3.4–53,905  nM) was used in addition to the standard 
dilutions to ensure accurate inhibitory concentrations 
could be determined. The top row of each plate served as 
a drug-free control.
Immediate ex vivo drug susceptibility assay
At the time of diagnosis (before treatment), fresh Plasmo-
dium isolates were tested for sensitivity to anti-malarials 
by culturing on dried drugs coated plates and measuring 
growth inhibition. For the P. vivax assay, blood samples 
were adjusted to 2% haematocrit in McCoy’s 5A medium 
supplemented with 20% AB blood-group serum, and 
added to dried drug coated plates. Plates were then incu-
bated at 37  °C in a candle jar for 24–48  h, and parasite 
maturation in drug-free wells was checked by microscopy 
at 24  h and then every 6  h until 48  h. Parasite growth 
inhibition over the established concentration ranges was 
measured by the microscopy-based schizont maturation 
test (SMT) using the modified WHO microtest [36, 37] 
for the first 19 P. vivax isolates with >  50% early stage 
parasites in initial samples and Plasmodium pan-species 
lactate dehydrogenase (pLDH) ELISA [31, 38] for all iso-
lates, side by side (Fig. 1). For the SMT, incubation was 
stopped when ≥ 40% of parasites in drug-free wells had 
reached the schizont stage. Thick smear examination of 
samples from each well was performed, and the number 
of schizonts per 200 asexual stage parasites for each drug 
concentration was determined. The number of schizonts 
were plotted against drug concentrations, and  IC50s were 
estimated by nonlinear regression analysis using Graph-
Pad Prism version 6.0. For the pLDH-ELISA assay, incu-
bation was stopped when ≥  40% schizont stages were 
reached in drug-free wells, or at 48 h if parasite cultures 
did not reach at least 40% schizonts. Plates were frozen 
and later thawed for analysis of growth inhibition using 
the pLDH-ELISA. pLDH optical density (OD) readings 
were plotted against drug concentrations, and  IC50s were 
estimated as described above. Samples with poor growth 
rates, defined as < 40% schizonts in drug-free wells or a 
pLDH-OD ratio < 1.7 between no-drug control wells and 
maximum tested drug concentrations, were excluded 
from data analysis for SMT or pLDH-ELISA, respectively. 
A “successful”  IC50 assay result was defined as achieving 
a sigmoidal concentration–response when testing serial 
drug dilutions for at least one of the tested drugs.
For the P. falciparum assay, the pLDH-ELISA [38] and 
the established histidine-rich protein-2 (HRP-2) ELISA 
[32] was used to simultaneously test field isolates and 
reference laboratory clones (W2 and 3D7). Culture con-
ditions used in the P. falciparum assay were adjusted to 
1.5% haematocrit in 0.5% Albumax RPMI 1640. Para-
site growth inhibition was assessed by pLDH-ELISA 
and HRP-2 ELISA after 48 and 72 h incubation, respec-
tively. The same incubation period (48 h) for P. vivax and 
P. falciparum were used in the pLDH ELISA to ensure 
meaningful comparison of susceptibility results. The pre-
viously established 72 h incubation was followed for the 
HRP-2 method.  IC50s were estimated as described above. 
Isolates with reduced susceptibility to PPQ capable of 
growing in maximum drug concentrations could not be 
interpolated using the standard PPQ dilution range (0.9–
674  nM). To accurately estimate  IC50 dose–response, 
the curve was replotted by fitting ‘zero-growth’ HRP2 or 
pLDH OD values at the extrapolated PPQ concentration 
of 53,905 nM [35, 39].
Plasmodium vivax multi‑drug resistance (pvmdr1) SNPs 
and copy number analysis
Genomic DNA was prepared from EDTA-anticoagulated 
blood using the QIAamp DNA Mini Kit (Qiagen) and 
used to analyse pvmdr1 Y976F and F1076L mutations 
and copy number variation. Multiplex real-time PCR was 
used to assess pvmdr1 copy number. The pvmdr1 (target) 
and pv aldolase (reference) genes were both amplified by 
RT-PCR, following methods described by Lin et al. [40]. 
Plasmids containing cloned fragments of pvmdr1 and 
pv aldolase, developed using the TOPO XL PCR Clon-
ing Kit (Invitrogen, Carlsbad, CA), were used as positive 
controls in each experiment. Reactions were performed 
in duplicate. Threshold cycle (Ct) values were used to cal-
culate the relative quantitation of pvmdr1 copy number 
by the Pfaffl method [41]. Copy number was determined 
by rounding to the nearest integer and was considered 
increased if >  1. For pvmdr1 Y976F and F1076L analy-
sis, PCR was performed to amplify a 647  bp region of 
the  pvmdr1  gene covering these SNPs, using the condi-
tions previously described in Lin et  al. and amplified 
products were directly sequenced [40].
Statistical analysis
Statistical analysis was performed using Graph-Pad 
Prism version 6.0 (GraphPad Software, Inc, San Diego, 
CA, USA). Parasite drug susceptibilities were expressed 
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as median  IC50s for all isolates. Differences in susceptibil-
ity between groups were determined using non-paramet-
ric Mann–Whitney or Kruskal–Wallis tests. Comparison 
of  IC50s attained from pLDH and HRP-2 ELISA were 
made using Wilcoxon matched pair testing. Assay cor-
relation was evaluated using Spearman’s correlation test. 
Spearman test was also used to examine the correlation 
between  IC50 and ratio of early/mature stage parasites 
(EM ratio) at start of assay to determine the effect of ini-
tial P. vivax stage on LDH-ELISA  IC50 results.
Results
Ex vivo P. vivax assay development using the schizont 
maturation test
An overall schematic for the experiment is shown in 
Fig.  1. Of 76 P. vivax isolates collected from Oddar 
Meanchey Province between June 2013 and October 
2015, 71 fresh isolates were tested for ex  vivo sensitiv-
ity to anti-malarials. Parasite density ranged from 2500 
to 38,000  µL−1 with variation in the initial parasite 
stage. Synchronous (≥  80%) early and mature tropho-
zoite stages were found in 13 and 19 samples, respec-
tively, while the rest included mixed stages. In an effort 
to improve suitability for the schizont maturation test 
(SMT) by synchronizing isolates at the early stage, the 
first 3 isolates were treated with 45% Percoll to separate 
late stage parasites and enrich for early stage. Although 
Percoll treatment helped to increase a proportion of 
early stages in samples, trophozoites remained, leading 
to failure to reach 80% early stage for all 3 samples. One 
explanation is that the density of 45% Percoll normally 
can separate the schizonts and very late trophozoites, 
leaving earlier trophozoites and ring stages in the sam-
ples. In addition, perfect separation efficiency of Percoll 
density centrifugation method may not be achievable in 
practice as even if synchronized late stages are found in 
interphase layer, mixed stage parasites may still be found 
in the pellet. The effect of white blood cell (WBC) deple-
tion processes on parasite maturation were compared for 
the first 29 isolates, but far fewer schizonts in drug-free 
wells were observed in WBC-depleted samples (0–29% 
schizonts), compared to whole blood samples (0–72% 
schizont). None of the WBC depleted samples reached 
the threshold for successful culture for SMT (≥ 40% schi-
zonts in drug-free wells) [37]. Given that neither Percoll 
treatment nor WBC depletion improved assay condi-
tions, both were abandoned. To examine the effects of 
WBC on the assay, the pLDH assay was run on whole 
blood and packed RBC specimens of these 29 P. vivax 
isolates, side by side. Good correlations were found for 
all drugs tested (ρ =  0.5–0.9, P  <  0.05), though slightly 
reduced  IC50s were found after removing WBC for 
DHA, AS, and CQ with median difference  of  =  −  0.6, 
− 0.8, − 6.2, respectively. No significant differences were 
found for other drugs. Reasonable correlation of results 
attained from both approaches suggested assay reliability 
when using whole blood samples.
In ex vivo assays of whole blood samples, erythrocytic 
P. vivax maturation was observed for all but 5 isolates 
in no-drug control wells over 48  h culture resulting in 
2–72% schizonts (median  =  21%). However, only 22 of 
71 isolates were able to develop to ≥ 40% schizonts. The 
time to maximum ex  vivo schizont growth varied from 
24 to 48  h, with a median of 48  h, though it tended to 
be earlier for cultures with mature trophozoite stages 
taking only 24–30  h. There was a positive correlation 
between higher ratios of early/mature trophozoites (EM 
ratio) and time taken to reach maximum schizont growth 
(Spearman ρ =  0.63; P < 0.001). Of the first 19 P. vivax 
isolates with > 50% early stage parasites in initial samples, 
SMT yielded an interpretable  IC50 in only 6 isolates (32% 
success rate). Since the SMT was found to have fewer 
interpretable results and was significantly more labour-
intensive than pLDH-ELISA, the SMT was not per-
formed in the remaining experiments.
Comparability of ex vivo Plasmodium falciparum 
susceptibility in the HRP‑2 and pLDH ELISA assays
Given the challenges of the SMT, the pLDH ELISA was 
evaluated next. In order to first establish the relevance 
of the pLDH ELISA assay for comparing P. falciparum 
to P. vivax resistance profiles, P. falciparum  IC50 results 
in our routinely used HRP-2 assay and the pLDH ELISA 
were compared. Figure 2 revealed similarities between P. 
falciparum isolate  IC50 in the HRP-2 and pLDH ELISA 
assays for chloroquine (CQ), lumefantrine (LUM), the 
artemisinins (ARTs), piperaquine (PPQ), and doxycycline 
(DOX). Wilcoxon pairwise  IC50 comparisons were signif-
icantly higher in the pLDH assay for mefloquine (MQ). 
Figure  3 illustrates global correlation for P. falciparum 
isolates susceptibility between the 2 assays. There were 
moderate to strong correlations between results obtained 
for P. falciparum isolates in the pLDH assay and HRP-2 
ELISAs for all drugs tested, with the exception of DOX. 
The latter findings were despite similarities in median 
values overall.
Comparison of ex vivo P. vivax and P. falciparum drug 
susceptibility in Cambodia 2013–2015 using the 
pLDH‑ELISA method
pLDH-ELISA  IC50s to anti-malarials of Cambodian P. 
vivax isolates collected during 2013–2015 are shown in 
Fig.  4. Limited SMT data as described above hindered 
meaningful comparison of results from these 2 assays. 
pLDH-ELISA  IC50 results from P. falciparum isolates col-
lected in the same area, and from laboratory clones are 
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also presented in Fig.  4 for comparison.  IC50 results of 
P. falciparum laboratory clones were able to successfully 
discriminate expected susceptibility profiles for the 3D7 
(CQ-sensitive, MQ-resistant) and W2 strains (CQ-resist-
ant, MQ-sensitive). pLDH-ELISA  IC50s were significantly 
lower for P. vivax than P. falciparum clinical isolates for 
dihydroartemisinin (DHA), artesunate (AS), and CQ, 
while no differences were found for LUM where both had 
low  IC50 or DOX where both had high  IC50 (Fig.  4). In 
contrast, pLDH-ELISA  IC50s of P. vivax isolates were sig-
nificantly higher for artemisone (ATM) and MQ than P. 
falciparum in this assay.
Both P. vivax and P. falciparum had comparable median 
PPQ  IC50 (106.5 vs 123.8  nM respectively), but some P. 
falciparum isolates were able to grow in much higher 
concentrations above the normal standard curve used 
(Fig. 4). Although a statistically significant difference was 
not detected initially when comparing PPQ susceptibility 
between P. vivax and P. falciparum based on the pLDH 
assay, 67% of P. falciparum isolates (39 out of 58 total) 
were found to survive exposure to maximum standard 
curve PPQ levels (674  nM). Some isolates were found 
to have few 100-fold greater  IC50s (470–22,000  nM) 
using a new testing paradigm with increased maximal 
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using pLDH and HRP-2 ELISA, side by side. Median differences (Δ) are indicated below each pairwise comparison with values from the respective 
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PPQ concentrations of 53,905  nM, compared to those 
obtained in previous years (< 50 nM). In contrast, none 
of the evaluated P. vivax isolates were able to grow in the 
highest tested PPQ concentration of 674 nM, suggesting 
greater overall susceptibility compared to P. falciparum. 
P. vivax susceptibility to PPQ increased over the period 
2013–2015, while there were minor fluctuations or no 
change in parasite susceptibility to the other drugs tested 
(Additional file 1).
In contrast to the SMT, pLDH-ELISA was able to 
determine  IC50 in 83% of P. vivax isolates (58/70) evalu-
ated, though success rate was drug dependent, ranging 
from 66 to 83% for most drugs. There was <  20% suc-
cess in achieving sigmoidal  IC50 curves for quinine (QN) 
and atovaquone (ATQ). High background optical den-
sity (OD) levels in maximally concentrated wells inter-
fered with interpretation. An OD ratio <  1.7 between 
drug-free control and maximum concentration wells 
precluded interpretable concentration–response curves. 
Therefore, QN and ATQ  IC50 results were excluded from 
the analysis. Likewise MQ had a lower success rate (39%) 
compared to other drugs. The high pLDH-OD back-
ground interference observed during QN, ATQ, and MQ 
testing was also observed in P. falciparum assays but 
had less effect on interpretability, and was not detected 
when P. falciparum was tested in the HRP-2 ELISA. The 
success rate of pLDH-ELISA for P. falciparum isolates 
ranged from 62 to 98% for all drugs tested.
Effect of initial P. vivax stage, assay incubation time 
and ex vivo growth efficiency on pLDH‑ELISA  IC50 results
To determine the effect of initial P. vivax stage on 
pLDH-ELISA results, the relationship between ini-
tial parasite stage and  IC50 was examined (Table  1). 
There was a negative correlation between early/mature 
trophozoite (EM) ratio and  IC50 for DOX (ρ  = −  0.7) 
with lesser effects observed for DHA, AS and LUM 
(ρ  =  −  0.3 to −  0.5). Three to four-fold greater  IC50 
for these drugs were detected in P. vivax isolates with 
synchronous mature trophozoites initially (EM ratio 
≤  0.25) than those with synchronous early stages (EM 
ratio ≥ 4). However, there was only a borderline correla-
tion between EM ratio and  IC50 for MQ, and no effect 
for other drugs.
The influence of assay incubation time on pLDH-
ELISA  IC50 results was examined, and there were notice-
able effects when testing DHA, AS, LUM, and DOX. 
There were significant increases in  IC50 for these drugs 
in isolates requiring shorter incubations (24–30 h) com-
pared to longer ones (42–48 h) (Kruskall–Wallis P value 
<  0.001–0.016). To assess the effect of ex  vivo growth 
efficiency on assay results, pLDH-ELISA  IC50 of isolates 
in the drug-free control assay reaching ≥ 40% schizonts 
(the designated threshold for SMT culture success) was 
compared with results of isolates having less growth effi-
ciency. There were no differences in  IC50 between the 2 
groups for any of the drugs tested (Table 2).
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Fig. 4 Ex vivo drug susceptibility of P. vivax and P. falciparum isolates collected from Oddar Meanchey Province (northern Cambodia) during 
2013–2015. pLDH-ELISA  IC50s of fresh P. vivax (PV) and P. falciparum (PF) isolates against commonly used anti-malarials are presented as black dot 
plots with black median bars, while SMT results for the only six evaluable PV isolates are indicated in blue. Circle represent PV isolates, while triangles 
represent PF. Median pLDH-ELISA  IC50 and numbers of evaluable isolates appear above the X-axis, and the P-values for the Mann–Whitney test 
comparing  IC50s of P. vivax and P. falciparum appear at the top of the graph. NS indicates not significant based on a P-value ≥ 0.05. pLDH-ELISA  IC50 
of W2 (green) and 3D7 (purple) reference clones obtained from three independent assays are presented in scatter dot plot with bars representing 
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Page 8 of 13Chaorattanakawee et al. Malar J  (2017) 16:392 
Plasmodium vivax drug resistance markers
Plasmodium vivax multi-drug resistance (pvmdr1) Y976F 
and F1076L mutations and copy number were analysed 
for 23 P. vivax isolates collected in 2013. Of 23 evalu-
ated isolates, pvmdr1 Y976F and F1076L mutations were 
found in 78% (17/23) and 83% (19/23), respectively, com-
posing 74% (17/23) double mutants, 9% (2/23) single 
F1076L mutants, and 17% (4/23) wild type isolates. None 
had pvmdr1 amplification.
Discussion
This is the first report of ex vivo P. vivax drug susceptibil-
ity testing of field isolates in Cambodia, providing impor-
tant baseline data for ongoing resistance surveillance. 
The focus of containment and elimination efforts in 
Cambodia to date has been multidrug resistant P. falcipa-
rum malaria. Relatively little is known about P. vivax drug 
sensitivity due to the inability to culture P. vivax long 
term. The pLDH method bypasses this critical limitation 
by using fresh isolates, making it potentially practical 
and informative for measuring ex  vivo P. vivax resist-
ance. While further validation of the assay is needed, the 
correlations observed with the  IC50 results with P. falci-
parum, in both the pLDH and previously established 
HRP-2 assays, lend support to its utility as a surveillance 
tool [32]. The P. falciparum HRP-2 assay has been care-
fully standardized in an effort to reliably produce inter-
pretable  IC50 results in P. falciparum field isolates over 
time [32]. However, it cannot be used in P. vivax which 
does not produce HRP-2. Unfortunately, we were unable 
to establish the P. vivax SMT using previously described 
methods. Potential explanations for the poor success rate 
of SMT could include low parasitaemia and drug residue 
in samples. Nearly 40% of P. vivax samples has parasitae-
mia <  0.1%, and issues of self-medication and unregu-
lated anti-malarial distribution in Cambodia are well 
documented [42]. Further, WBC depletion process seems 
to retard P. vivax growth leading to failure for SMT. The 
loss of P. vivax and time spent during the WBC filtration 
process could be possible reasons. However, less effect 
was observed in pLDH ELISA in which  IC50 from whole 
blood, and WBC depleted samples testing were well cor-
related. This corresponded with the previous finding on 
P. falciparum HRP-2 method, suggesting the reliability 
of assay on whole blood sample without WBC remov-
ing [43]. Overall, in addition to being a field expedi-
ent method, the pLDH method was able to reveal some 
important information about P. vivax susceptibility.
With the possible exception of chloroquine, blood stage 
P. vivax is generally thought to have remained susceptible 
to a wide variety of anti-malarials, though data is limited. 
Using the pLDH-ELISA, P. vivax appeared significantly 
more susceptible to dihydroartemisinin (DHA), artesu-
nate (AS), and chloroquine (CQ) than P. falciparum,but 
less susceptible to mefloquine (MQ), and artemisone 
(ATM), and similarly susceptible to lumefantrine (LUM), 
Table 1 Effect of initial P. vivax stage on pLDH-ELISA  IC50 results
* Statistical significance
Drug Spearman correlation test Mann–Whitney U test P value
for  IC50 and EM ratio EM ratio ≥ 4 EM ratio ≤ 0.25
N coefficient P‑value N median  IC50 N median  IC50
DHA 57 − 0.34* 0.009* 11 2.6 12 7.5* 0.008*
AS 56 − 0.46* < 0.001* 11 2.9 11 9.4* < 0.001*
CQ 46 − 0.12 0.445 12 23.8 4 28.1 0.716
PPQ 52 − 0.01 0.922 12 104.3 7 99.5 0.612
LUM 34 − 0.42* 0.014* 4 5.6 7 25.4* 0.023*
DOX 35 − 0.70* < 0.001* 5 12,680 9 42,667* 0.003*
ATM 23 − 0.12 0.593 3 0.61 7 2.0 0.137
MQ 27 − 0.39 0.046* 4 161.2 4 203.7 0.083
Table 2 There was little effect of  ex  vivo P. vivax growth 
on pLDH-ELISA  IC50 results
Drug Maximum number of schizonts P value of Mann–
Whitney U test
< 40% schizont ≥ 40% schizont
N median  IC50 N median  IC50
DHA 37 3.0 20 4.1 0.108
AS 37 3.0 19 3.5 0.166
CQ 32 22.1 14 22.1 0.981
PPQ 35 108.0 17 105.0 0.513
LUM 23 7.3 11 9.3 0.118
DOX 24 16,021 11 31,326 0.102
ATM 15 0.6 8 1.0 0.175
MQ 19 150.0 8 179.1 0.426
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piperaquine (PPQ) and doxycycline (DOX). It should be 
noted that although DOX  IC50 values were in the micro-
molar range, they were still below previously proposed 
values for resistance [44]. The present study reveals Cam-
bodian P. vivax isolates appear to remain sensitive to CQ 
while resistance to other anti-malarials may be worse 
than previously assumed, though the absence of base-
line values precludes definitive conclusions. Although 
previously established, well-controlled pLDH methods 
were used here to test both P. vivax and P. falciparum, 
inter-species difference and assay bias between 2 species 
cannot be ruled out. Inter-species comparisons require 
careful interpretation, especially in the absence of base-
line data. In addition, mixed parasite stages found in P. 
vivax samples may confound pLDH results for drugs with 
stage-specific activity. It is possible that the pLDH results 
of P. vivax here represent an average overall susceptibil-
ity of mixed parasite stages. As an example, our findings 
indicated that mixed stage P. vivax remained susceptible 
to CQ, though CQ has specific ring stage activity [37].
The present study brings to light important meth-
odologic considerations for assessing P. vivax resist-
ance in vitro. The effect of parasite growth efficiency on 
P. vivax pLDH assay was minimal. There were not sig-
nificant differences in pLDH-ELISA  IC50 for most drugs 
tested between isolates reaching ≥  40% schizonts and 
those with less growth. Thus, the pLDH assay had utility 
even in P. vivax isolates failing to reach the 40% schizont 
target required for the SMT. pLDH-ELISA validity was 
also confirmed by successful discrimination of known 
susceptibility profiles for 3D7 (CQ sensitive, MQ-resist-
ant) and W2 (CQ-resistant, MQ-sensitive) P. falciparum 
laboratory strains. When testing P. falciparum clinical 
isolates, pLDH-ELISA was able to detect PPQ resist-
ance at several 100-fold higher  IC50, corresponding with 
results from the 72  h HRP-2 ELISA. Comparison with 
these previously well benchmarked assays further sup-
ports use of pLDH-ELISA for P. vivax isolate drug sus-
ceptibility testing.
Based on our pLDH-ELISA results, stage-specific drug 
activity on P. vivax growth was apparent for DOX and AS, 
but less pronounced for DHA, LUM and MQ (Table 1). 
Isolates initially at the trophozoite stage had significantly 
higher  IC50s to these drugs than those initially at the ring 
stage. Specific activity of chloroquine on ring stages, pre-
viously described for the schizont maturation test (SMT), 
was not detected here using the pLDH-ELISA. Compara-
tive P. vivax testing at ring and trophozoite stages for 
the same isolates may confirm stage-specific activity of 
these drugs. Duration of drug incubation in the SMT is 
another factor previously reported to influence in  vitro 
drug responses for P. vivax [37]. A prior statistical mod-
elling study of SMT dose–response data indicated that 
only assays with initial ring stage parasitaemia ≥ 65% and 
a duration ≥ 35 h produce robust  IC50 values [45]. More 
data is required to identify the threshold where the asso-
ciation between  IC50 assay duration and parasite stage 
composition disappears in the pLDH ELISA.
Comparing findings of the present study to those 
reported previously for P. falciparum and P. vivax iso-
lates from the Brazilian Amazon [46, 47] and Indonesia 
[36, 48, 49] using pLDH ELISA and SMT assays, Cam-
bodian isolates were found to be less susceptible to MQ 
and PPQ. However, Cambodian and Brazillian P. vivax 
isolates were more sensitive to CQ than in Papua Indo-
nesia where P. vivax CQ resistance has emerged. Another 
ex vivo study reported P. vivax CQ resistance in 60% of 
isolates collected from the Thai-Myanmar border, and 
higher median  IC50 than in Cambodia [50]. Although, 
comparability of the SMT and pLDH ELISA have yet to 
be formally established, these regional differences are not 
surprising. Reduced MQ and PPQ susceptibility of Cam-
bodian isolates reflects higher drug pressure in the region 
from long term use. High grade PPQ resistance recently 
emerged in P. falciparum with resultant effects on sym-
patric P. vivax infection [10, 30]. Chloroquine resistant 
P. vivax infections have been detected in Indonesia since 
the 1990s and, in 2008, the national treatment guidelines 
for P. vivax were changed to ACT [51]. Approximately 
60% of P. vivax patients treated with chloroquine experi-
enced a recurrence within 28 days in studies from Malay-
sia and Vietnam [24, 52]. Yet chloroquine sensitivity was 
better preserved in studies conducted in Cambodia [29, 
44], the Brazilian Amazon [53], Myanmar [54], India [55] 
and Ethiopia [56].
Piperaquine phosphate  IC50s of Cambodian P. vivax 
isolates were higher than Indonesia, but the median was 
similar to those of P. falciparum from the same region. 
However, some Cambodian P. falciparum isolates were 
able to grow in much higher PPQ concentrations with up 
to 100-fold greater  IC50s than P. vivax, suggesting greater 
overall susceptibility in P. vivax compared to P. falcipa-
rum. In 2012, AS–MQ was replaced with DHA-PPQ as 
national first-line treatment for both P. falciparum and 
P. vivax [57]. Since reduced ex  vivo P. falciparum PPQ 
sensitivity of Cambodian isolates has corresponded with 
high grade failure of DHA–PPQ treatment in this region 
[10, 35], it raises a concern that DHA–PPQ may also 
become less effective for P. vivax. Unlike P. falciparum, 
P. vivax does not exhibit concomitant artemisinin resist-
ance. In the absence of an established baseline value, it is 
possible that P. vivax has higher intrinsic PPQ  IC50 in the 
assay than P. falciparum. Further, the decline observed 
in P. vivax  IC50 after PPQ was introduced in 2013 may 
have been the result of a decline in overall parasite fit-
ness in response to developing mutations, similar to 
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previous observations in P. falciparum [58]. Regardless, 
clinical correlations are necessary to define the impact of 
increased PPQ  IC50s for P. vivax. Also to be explored is 
whether the change in treatment policy for P. vivax may 
have relieved chloroquine pressure. However, ongoing P. 
falciparum chloroquine resistance comparable to previ-
ously observed levels [9, 34] argues against this. Resist-
ance in both parasite species would have been expected 
to subside if exposure had truly been reduced [59]. Defin-
itive demonstration of assay utility will require compari-
son of ex vivo pLDH-ELISA results with clinical response 
in well-controlled P. vivax field studies. Limited ability to 
distinguish recrudescence, relapse, and reinfection clini-
cally may confound interpretation.
While molecular data in the present study was lim-
ited by convenience sampling, and available resources, 
it does offer a few useful observations. The mechanism 
of CQ resistance in P. vivax remains unclear although 
a few studies have suggested associations with P. vivax 
multi-drug resistance gene (pvmdr1) Y976F mutation 
and pvcrt-o expression [17, 60]. In northern Cambo-
dian isolates, pvmdr1 Y976F mutants were observed at 
extremely high frequency yet when tested in the ex vivo 
assay, the isolates are CQ-sensitive. Accordingly, CQ has 
retained clinical efficacy as a P. vivax rescue agent in tri-
als conducted there over the past several years by the 
USAMD-AFRIMS [29]. This argues against the useful-
ness of the Y976F mutation as a CQ resistance marker 
[17]. No pvmdr1 amplification was detected in Cambo-
dian isolates, precluding correlation with ex  vivo drug 
susceptibility to chloroquine or other anti-malarials. No 
attempt to measure stage-specific pvcrt-o expression in 
these clinical isolates was made here. Comparing our 
findings to those reported previously from other regions 
revealed geographical differences in pvmdr1 amplifica-
tion and mutation prevalence. The prevalence of Y976F 
and F1076L mutations were high in Cambodia, Indone-
sia, and Papua New Guinea (70–100%) [36, 61, 62], but 
no mutant was detected in Brazil [47, 60]. Moderate rates 
of mutation were previously found in Thailand (18–23% 
for Y976F and 53–61% for F1076L) [50, 62]. Correspond-
ing to previous findings [40], most Cambodian isolates 
were double mutants (74%), with single F1076L mutants 
found in < 10%. The prevalence here differed compared 
to Thailand where a single F1076L mutation was seen in 
> 60%. No pvmdr1 amplification was detected in north-
ern Cambodian isolates tested in the present study, 
despite reduced susceptibility to MQ. It is possible that 
if more sensitive assays targeting the pvmdr1 breakpoint 
were used [63], minority clones with pvmdr1 amplifi-
cation may have been detected, given the polyclonal 
nature of vivax infections in this region [64–66]. Pvmdr1 
amplification rates of 4–37% have been observed in other 
regions of the country [30, 40]. Similarly, a 7–39% ampli-
fication rate was reported in Thailand [40, 62]. There was 
no pvmdr1 amplification in Indonesia [36, 67] and low 
prevalence in Brazil (0.9–4%) [67, 68]. The lack or low 
rate of pvmdr1 amplification in some areas of Thailand 
and Cambodia with intense MQ pressure does not sup-
port previous evidence associating pvmdr1 amplification 
with MQ pressure [67].
Although the pLDH-ELISA  IC50 assay as described 
here represents an important first step to assess P. vivax 
drug susceptibility, the following caveats must be consid-
ered. The confounding factors of mechanism and speed 
of drug action must be taken into account when inter-
preting results obtained using different in vitro methods. 
High optical density (OD) background interference in 
wells containing maximal concentrations of some drugs 
tested caused low growth ratios and failure to achieve 
sigmoidal  IC50 curves. This phenomenon was reported 
previously to depend on the nature of the drug being 
tested and detection methodology. Relatively higher OD 
background tends to be observed in non-artemisinin 
drugs with a more pronounced effect in ELISA-based 
assays [69, 70]. This may relate to the later onset of action 
of non-artemisinins in the parasite life cycle, allowing 
ring stage parasites to continue to produce the proteins 
being assayed despite high drug concentrations. This may 
explain paradoxical growth seen at high concentrations 
of non-artemisinins common in the pLDH-ELISA, but 
less frequently in the HRP2-ELISA, and not at all in the 
microscopy-based SMT [69, 70]. This corresponds with 
the observation of parasite growth in high concentrations 
of atovaquone, mefloquine, and quinine in the pLDH-
ELISA assay for both P. falciparum and P. vivax, but not 
in the HRP2 ELISA or SMT. The SMT’s relatively low 
throughput, and challenges interpreting concentration–
response curves for parasite cultures unable to develop 
to the threshold of ≥ 40% schizonts may limit its useful-
ness. The assay requires extensive experience on stage 
differentiation by operators to be effective and replicable. 
However, as the malaria map continues to shrink in Cam-
bodia, it may be possible to better concentrate the expert 
microscopy skills needed to adequately perform the SMT 
in areas of greatest need.
Conclusion
Overall, the pLDH-ELISA has the potential to be a use-
ful and replicable method to assess ex  vivo P. vivax 
resistance in field isolates in Cambodia with reasonable 
throughput. Results correlated well with those observed 
for P. falciparum in both the pLDH and better estab-
lished HRP-2 assays. While current malaria elimination 
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efforts are focused on resistant P. falciparum malaria, 
P. vivax malaria may ultimately prove more difficult to 
eliminate due to its ease of transmission, dormancy, and 
only primaquine being effective at preventing P. vivax 
relapse. Current tools are also inadequate to differenti-
ate relapse and recrudescence from re-infection. Evalua-
tion of ex vivo P. vivax susceptibility using field isolates 
will likely prove a useful part of the armamentarium to 
monitor for growing resistance and predict risk of treat-
ment failures. Clinical P. vivax resistance can be difficult 
to detect due to difficulty distinguishing relapsing disease 
from recrudescence and/or reinfection, and the pLDH 
assay may prove a useful adjunct in this regard. Incorpo-
rating ex vivo pLDH monitoring with therapeutic efficacy 
studies for individuals with P. vivax is advised to further 
validate this field-expedient method.
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